➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
McKesson
Medtronic
Dow
McKinsey

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,050,309


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,050,309 protect, and when does it expire?

Patent 9,050,309 protects EPANOVA and is included in one NDA.

This patent has forty-nine patent family members in thirty-four countries.

Summary for Patent: 9,050,309
Title:DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Abstract: DPA-enriched pharmaceutical compositions of polyunsaturated fatty acids in free acid form, therapeutic methods for their use, and processes for refining the compositions from fish oil are presented.
Inventor(s): Maines; Timothy J. (Potomac, MD), Machielse; Bernardus N M (North Potomac, MD), Mehta; Bharat M. (Mendham, NJ), Wisler; Gerald L. (Windermere, FL), Davidson; Michael H. (Highland Park, IL), Wood; Peter Ralph (Cotherstone, GB)
Assignee: Omthera Pharmaceuticals, Inc. (Princeton, NJ) Chrysalis Pharma AG (Sacheln, CH)
Application Number:13/797,557
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,050,309

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms EPANOVA omega-3-carboxylic acids CAPSULE;ORAL 205060-001 May 5, 2014 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,050,309

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013201793   Start Trial
Brazil 112014016788   Start Trial
Canada 2860512   Start Trial
Chile 2014001803   Start Trial
China 104321055   Start Trial
China 107050457   Start Trial
China 108524483   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Boehringer Ingelheim
Merck
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.